Global Ganja Report

After last weekend's horrorshow in Charlottesville, it's a relief that the white supremacist hate-fest planned for Boston on Aug. 19 (sickeningly billed as a "Free Speech" rally) was a total bust. Just some 40-odd "alt-right" protesters gathered on the historic Boston Common, dwarfed by about 40,000 counter-protesters, who chanted "wrong side of history" and "shame, shame." Eventually, police escorted the small group of haters with their Nazi regalia away to safety, and that was that.

Amid all the current paranoia about hackers infiltrating the highest levels of American politics comes the disturbing news that software used by cannabis businesses in over 20 states was attacked and compromised. The story was reported both by the cannabis industry trade website Marijuana Business Daily and tech sites that monitor such attacks, including Hackbusters and DataBreaches. The software, known as MJ Freeway, is used for "seed-to-sale" tracking of cannabis in states that have legalized or passed medical marijuana laws. The Denver-based company said its main servers and backup system both went down the morning of Jan. 8, and remained offline as of the next afternoon.

After the first day of Senate confirmation hearings for Jeff Sessions, president-elect Trump's choice to lead the US Justice Department, cannabis advocates are parsing his testimony for clues as to what the incoming administration's stance will be on whether to continue to give breathing room to state-level legalization and medical marijuana laws. The Los Angeles Times takes an ominous view, writing in a headline: "Sessions leaves door open to reviving federal war on pot."

Denver-based AmeriCann is planning to develop what will be the United States' largest medical marijuana facility in Freetown, Mass. At one million square feet, the Massachusetts Medical Cannabis Center is planned for a tract in the Bristol County town formerly slated for a brewery by the Boston Beer Co. Boston Business Journal reports that AmeriCann bought the property this fall for $4.475 million. AmeriCann CEO Tim Keogh said the facility will be "the place in the northeast US for the creation of a wide variety of exciting new advanced products for medical cannabis patients."

The results of the Nov. 8 elections really indicate the schizophrenic nature of American political culture at this moment. Amid the fear and loathing over the election of the fascistic Donald Trump as president, big gains were registered for cannabis freedom. Voters in California approved Proposition 64, legalizing  up to an ounce for those 21 and older, and allowing individuals to grow up to six plants. The measure also permits retail sales and imposes a 15% tax. Similar measures passed in Massachusetts, Maine and Nevada, bringing the percentage of Americans living in states where cannabis is legal for adults up from five to 20 percent. Only Arizona's Proposition 205 was rejected by the voters.

Who do you think is pouring money into the campaigns against the legalization initiaves that will go before the voters in five states next month? Well, an Oct. 22 exposé in The Guardian newspaper will confirm your most cyniical suspicions. In August, the pharmaceutical company Insys Therapeutics became the biggest donor to the campaign to defeat Arizona's Proposition 205, making a $500,000 donation to Arizonans for Responsible Drug Policy (ARDP). In making the donation, Insys cited concerns for child safety. But The Guardian points out the delicious irony: Insys manufactures Subsys, a prescription painkiller derived from fentanyl—a synthetic opioid that is up to 100 times more powerful than morphine. And the Phoenix New Times adds that Insys is under investigation in four states, including Arizona, for marketing practices related to Subsys that have allegedly resulted in patient deaths.

On June 27, Massachusetts' Department of Public Health rejected an application from Green Heart Holistic Health and Pharmaceuticals to operate a dispensary in Boston, despite giving the company initial approval. The reason stated for the denial is Steve DeAngelo's criminal record. Controversy over the Green Heart dispensary, awarded to Andrew DeAngelo, erupted when Steve's participation as the financial backer and "strategic adviser" was revealed. Since Steve wouldn't be physically working at the store, his name was not included in the application. DeAngelo pleaded guilty on Aug. 6, 2001 of possession of cannabis with intent to distribute and received a five-year suspended sentence and three years' probation.

The Cannabis Committee of the American Herbal Products Association (AHPA) issued recommendations this week to regulators of dispensaries in California, Colorado, and Massachusetts, and will make similar recommendations in other medical marijuana states over the next days. The committee, in cooperation with Americans for Safe Access (ASA), has over the past year coordinated the development of best practice protocols in several areas, including cultivation; manufacturing, packaging and labeling; laboratory practice; and distribution.